Shareholders' Deficit (Details) - USD ($) |
1 Months Ended | 2 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 03, 2021 |
May 04, 2021 |
Apr. 07, 2021 |
Apr. 01, 2021 |
Mar. 08, 2021 |
Feb. 01, 2021 |
Jan. 18, 2021 |
Jan. 07, 2021 |
Jan. 06, 2021 |
May 08, 2020 |
Apr. 17, 2020 |
Jan. 13, 2020 |
Dec. 12, 2019 |
Apr. 28, 2021 |
Mar. 19, 2021 |
Feb. 24, 2021 |
Aug. 20, 2020 |
Feb. 20, 2020 |
Feb. 18, 2020 |
Apr. 28, 2021 |
Jun. 30, 2021 |
Jun. 30, 2020 |
Jun. 30, 2021 |
Jun. 30, 2020 |
Dec. 31, 2020 |
Jul. 22, 2021 |
Mar. 31, 2021 |
Apr. 28, 2020 |
|
| Shareholders' Deficit (Details) [Line Items] | ||||||||||||||||||||||||||||
| Accrued dividend payable | $ 6,885 | |||||||||||||||||||||||||||
| Common shares per share (in Dollars per share) | $ 0.04 | |||||||||||||||||||||||||||
| Gross proceeds | $ 161,000 | |||||||||||||||||||||||||||
| Investor purchase (in Shares) | 7,000,000 | |||||||||||||||||||||||||||
| Common shares per share (in Dollars per share) | $ 20,000 | $ 0.023 | $ 0.001 | $ 0.001 | $ 0.001 | $ 0.025 | $ 0.04 | |||||||||||||||||||||
| Stock-based professional fees | $ 6,000 | $ 292,193 | $ 150,539 | $ 516,946 | $ 287,080 | |||||||||||||||||||||||
| Prepaid expenses | $ 38,250 | $ 38,250 | ||||||||||||||||||||||||||
| Common stock issued (in Shares) | 241,050,965 | 241,050,965 | 228,346,974 | 500,000 | ||||||||||||||||||||||||
| Common stock per share (in Dollars per share) | $ 0.04 | |||||||||||||||||||||||||||
| Accretion amount | 5,000 | |||||||||||||||||||||||||||
| Consulting fees | 15,000 | |||||||||||||||||||||||||||
| Prepaid expenses | $ 24,050 | |||||||||||||||||||||||||||
| Vesting period | 9 months | |||||||||||||||||||||||||||
| Common stock, description | On April 7, 2021, the Company issued 2,500,000 shares of its common stock for investor relations services to be rendered. These shares were valued at $135,000, or $0.054 per common share, based on the quoted closing price of the Company’s common stock on the measurement date. In connection with these shares, the Company recorded stock-based professional fees of $135,000. | |||||||||||||||||||||||||||
| Company issued (in Shares) | 200,000 | |||||||||||||||||||||||||||
| Common share value | $ 6,000 | |||||||||||||||||||||||||||
| Closing price per share (in Dollars per share) | $ 0.03 | |||||||||||||||||||||||||||
| Stock-based professional fees | $ 43,250 | |||||||||||||||||||||||||||
| Accretion of stock-based professional fees | $ 5,000 | |||||||||||||||||||||||||||
| Stock-based compensation, description | Pursuant to this employment agreement, the Company agreed to grant a restricted stock award of 200,000 common shares of the Company which will vest on May 1, 2021. If the employee’s employment is terminated without cause or for good reason (both as defined in the employment agreement), or a change of control event (as defined in the employment agreement) occurs, these shares will immediately vest. For any other termination of employment, unvested restricted stock shall immediately terminate. These shares were valued on the date of grant at $8,000, or $0.04 per common share, based on contemporaneous common share sales. In connection with these shares, the Company shall record stock-based compensation over the vesting period. | |||||||||||||||||||||||||||
| Aggregate common shares (in Shares) | 6,750,000 | |||||||||||||||||||||||||||
| Stock based compensation value | $ 270,000 | |||||||||||||||||||||||||||
| Vested date | May 01, 2021 | |||||||||||||||||||||||||||
| Equity vested rate | 100.00% | |||||||||||||||||||||||||||
| Issued shares of common stock (in Shares) | 1,008,000 | |||||||||||||||||||||||||||
| Stock-based compensation expense on granted non-vested | $ 159,746 | 287,587 | $ 159,746 | 287,587 | ||||||||||||||||||||||||
| Unrecognized compensation expense | 126,504 | |||||||||||||||||||||||||||
| Shares of common stock upon conversion (in Shares) | 151,456 | |||||||||||||||||||||||||||
| Accounts payable | $ 6,058 | |||||||||||||||||||||||||||
| Common shares converted (in Shares) | 203,125 | |||||||||||||||||||||||||||
| Accrued interest | $ 16,250 | |||||||||||||||||||||||||||
| Cashless exercise of warrants (in Shares) | 1,050,000 | |||||||||||||||||||||||||||
| Compensation expense related to stock options | 0 | $ 382,615 | ||||||||||||||||||||||||||
| Total unrecognized compensation expense related to unvested stock options | 0 | 0 | ||||||||||||||||||||||||||
| Warrant purchase, description | the Company issued 1,008,000 shares of its common stock in connection with the cashless exercise of 1,050,000 warrants. The exercise price was based on contractual terms of the related warrant. | |||||||||||||||||||||||||||
| Business Development [Member] | ||||||||||||||||||||||||||||
| Shareholders' Deficit (Details) [Line Items] | ||||||||||||||||||||||||||||
| Common shares per share (in Dollars per share) | $ 0.066 | $ 0.078 | $ 0.10 | |||||||||||||||||||||||||
| Shares of grant restricted stock award of common shares (in Shares) | 100,000 | |||||||||||||||||||||||||||
| Value of grant restricted stock award of common shares | $ 49,500 | $ 54,600 | $ 10,000 | |||||||||||||||||||||||||
| Stock-based professional fees | $ 6 | $ 10,000 | 36,667 | |||||||||||||||||||||||||
| Prepaid expenses | 12,833 | 12,833 | ||||||||||||||||||||||||||
| Aggregate shares of common stock (in Shares) | 750,000 | 700,000 | ||||||||||||||||||||||||||
| Workers' Compensation Insurance [Member] | ||||||||||||||||||||||||||||
| Shareholders' Deficit (Details) [Line Items] | ||||||||||||||||||||||||||||
| Prepaid expenses | 30,550 | 30,550 | ||||||||||||||||||||||||||
| Investor [Member] | ||||||||||||||||||||||||||||
| Shareholders' Deficit (Details) [Line Items] | ||||||||||||||||||||||||||||
| Purchase of shares (in Shares) | 7,000,000 | |||||||||||||||||||||||||||
| Cash proceeds from investor | $ 280,000 | |||||||||||||||||||||||||||
| Common shares per share (in Dollars per share) | $ 0.04 | |||||||||||||||||||||||||||
| Shares Issued for Accounts Payable [Member] | ||||||||||||||||||||||||||||
| Shareholders' Deficit (Details) [Line Items] | ||||||||||||||||||||||||||||
| Common shares per share (in Dollars per share) | $ 0.031 | |||||||||||||||||||||||||||
| Company issued (in Shares) | 3,801,224 | |||||||||||||||||||||||||||
| Accounts payable | $ 117,838 | |||||||||||||||||||||||||||
| Issued for Debt Conversion [Member] | ||||||||||||||||||||||||||||
| Shareholders' Deficit (Details) [Line Items] | ||||||||||||||||||||||||||||
| Debt conversion, description | the Company issued 13,275,000 shares of its common stock upon the conversion of convertible notes with bifurcated embedded conversion option derivatives including principal of $74,250, accrued interest of $28,085, and fees of $1,750. The conversion price was based on contractual terms of the related debt. The Company accounted for the partial conversion of these convertible notes pursuant to the guidance of ASC 470-20, Debt with Conversion and Other Options. Under ASC 470-20, the Company recognized an aggregate loss on debt extinguishment upon conversion in the amount of $123,455 which is associated with the different between the fair market value of the shares issued upon conversion and the conversion price and is equal to the fair value of the additional shares of common stock transferred upon conversion. | |||||||||||||||||||||||||||
| Consulting Agreement [Member] | ||||||||||||||||||||||||||||
| Shareholders' Deficit (Details) [Line Items] | ||||||||||||||||||||||||||||
| Common shares per share (in Dollars per share) | $ 0.04 | |||||||||||||||||||||||||||
| Shares of grant restricted stock award of common shares (in Shares) | 1,250,000 | |||||||||||||||||||||||||||
| Value of grant restricted stock award of common shares | $ 50,000 | |||||||||||||||||||||||||||
| Stock-based professional fees | $ 33,333 | |||||||||||||||||||||||||||
| Prepaid expenses | $ 16,667 | $ 16,667 | ||||||||||||||||||||||||||
| General Release Agreement [Member] | ||||||||||||||||||||||||||||
| Shareholders' Deficit (Details) [Line Items] | ||||||||||||||||||||||||||||
| Accrued compensation | $ 40,625 | |||||||||||||||||||||||||||
| Common shares per share (in Dollars per share) | $ 0.059 | |||||||||||||||||||||||||||
| Issued shares of common stock (in Shares) | 944,767 | |||||||||||||||||||||||||||
| Value of issued shares of common stock | $ 55,741 | |||||||||||||||||||||||||||
| Stock-based compensation | $ 15,116 | |||||||||||||||||||||||||||
| Sales Manager [Member] | ||||||||||||||||||||||||||||
| Shareholders' Deficit (Details) [Line Items] | ||||||||||||||||||||||||||||
| Common shares per share (in Dollars per share) | $ 0.078 | |||||||||||||||||||||||||||
| Vested date | May 01, 2022 | |||||||||||||||||||||||||||
| Issued shares of common stock (in Shares) | 200,000 | |||||||||||||||||||||||||||
| Value of issued shares of common stock | $ 15,600 | |||||||||||||||||||||||||||
| Officer [Member] | ||||||||||||||||||||||||||||
| Shareholders' Deficit (Details) [Line Items] | ||||||||||||||||||||||||||||
| Common shares per share (in Dollars per share) | $ 0.066 | |||||||||||||||||||||||||||
| Shares of grant restricted stock award of common shares (in Shares) | 2,500,000 | |||||||||||||||||||||||||||
| Value of grant restricted stock award of common shares | $ 165,000 | |||||||||||||||||||||||||||
| Vested date | May 01, 2022 | |||||||||||||||||||||||||||
| Series B Preferred Stock [Member] | ||||||||||||||||||||||||||||
| Shareholders' Deficit (Details) [Line Items] | ||||||||||||||||||||||||||||
| Designations established share (in Shares) | 100,000 | |||||||||||||||||||||||||||
| Preferred Stock par value (in Shares) | 0.10 | |||||||||||||||||||||||||||
| Stated value | $ 1,000 | |||||||||||||||||||||||||||
| Preferred Stock dividend Rate | 2.00% | |||||||||||||||||||||||||||
| Stock option, description | The Series B is convertible into common stock at the option of a holder or if the closing price of the common stock exceeds 400% of the Conversion Price for a period of twenty consecutive trading days, at the option of the Company. Conversion Price means a price per share of the common stock equal to 100% of the lowest daily volume weighted average price of the common stock during the two years preceding or subsequent two years following the Issuance Date, subject to adjustment as otherwise provided in the Certificate of Designations (the “Conversion Price”). | |||||||||||||||||||||||||||
| Accrued compensation | $ 295,000 | |||||||||||||||||||||||||||
| Accrued compensation shares (in Shares) | 295 | |||||||||||||||||||||||||||
| Stock based compensation | $ 3,778,810 | |||||||||||||||||||||||||||
| Accrued dividend payable | 9,362 | $ 2,476 | ||||||||||||||||||||||||||
| Preferred stock balance | 731,332 | 731,332 | 429,446 | |||||||||||||||||||||||||
| Liquidation value | 721,970 | 721,970 | 426,970 | |||||||||||||||||||||||||
| Series C Preferred Stock [Member] | ||||||||||||||||||||||||||||
| Shareholders' Deficit (Details) [Line Items] | ||||||||||||||||||||||||||||
| Designations established share (in Shares) | 100,000 | |||||||||||||||||||||||||||
| Preferred Stock par value (in Shares) | 0.10 | |||||||||||||||||||||||||||
| Stated value | $ 100 | 1,330,000 | ||||||||||||||||||||||||||
| Preferred Stock dividend Rate | 2.00% | |||||||||||||||||||||||||||
| Accrued dividend payable | 20,962 | 6,031 | ||||||||||||||||||||||||||
| Preferred stock balance | 1,600,962 | 1,600,962 | $ 1,336,031 | |||||||||||||||||||||||||
| Liquidation value | $ 1,580,000 | 1,580,000 | ||||||||||||||||||||||||||
| Percentage of stated value | 150.00% | |||||||||||||||||||||||||||
| Outstanding shares percent | 4.99% | |||||||||||||||||||||||||||
| Series C Convertible Preferred Stock [Member] | ||||||||||||||||||||||||||||
| Shareholders' Deficit (Details) [Line Items] | ||||||||||||||||||||||||||||
| Accrued dividend payable | $ 2,845,238 | $ 14,931 | ||||||||||||||||||||||||||
| Purchase of shares (in Shares) | 2,500 | |||||||||||||||||||||||||||
| Series A Preferred Stock [Member] | ||||||||||||||||||||||||||||
| Shareholders' Deficit (Details) [Line Items] | ||||||||||||||||||||||||||||
| Preferred shares, description | the Company issued 9,982,616 shares its common stock upon the conversion of 159,600 shares of Series A preferred with a stated redemption value of $159,600 and related accrued dividends payable of $3,192. The conversion price was based on contractual terms of the related Series A preferred shares. Upon conversion, the Company reclassified put premium of $37,438 to paid-in capital. | |||||||||||||||||||||||||||
| Maximum [Member] | Series C Convertible Preferred Stock [Member] | ||||||||||||||||||||||||||||
| Shareholders' Deficit (Details) [Line Items] | ||||||||||||||||||||||||||||
| Stated value | $ 250,000 | |||||||||||||||||||||||||||
| Minimum [Member] | Series C Convertible Preferred Stock [Member] | ||||||||||||||||||||||||||||
| Shareholders' Deficit (Details) [Line Items] | ||||||||||||||||||||||||||||
| Stated value | $ 100.00 | |||||||||||||||||||||||||||
| 2018 Long-Term Incentive Plan [Member] | ||||||||||||||||||||||||||||
| Shareholders' Deficit (Details) [Line Items] | ||||||||||||||||||||||||||||
| Stock option, description | The aggregate number of shares of common stock and number of shares of the Company’s common stock that may be subject to incentive stock options granted under the 2018 Plan is 50,000,000 shares, of which 11,445,698 shares have been issued or granted under incentive stock options and 28,451,070 shares of restricted stock have been issued as of June 30, 2021. | |||||||||||||||||||||||||||
| Aggregate shares of common stock (in Shares) | 25,000,000 | |||||||||||||||||||||||||||
| Description of options to acquire common stock | The exercise price of options granted under our 2018 Plan must at least be equal to the fair market value of the Company’s common stock on the date of grant and the term of an option may not exceed ten years, except that with respect to an incentive stock option granted to any employee who owns more than 10% of the voting power of all classes of the Company’s outstanding stock as of the grant date the term must not exceed five years and the exercise price must equal at least 110% of the fair market value on the grant date. | |||||||||||||||||||||||||||